nach oben

Erschienen in:

01.06.2013 | Original article

Positron-emission tomography CT to identify local recurrence in stage I lung cancer patients 1 year after stereotactic body radiation therapy

verfasst von: Prof. Dr. M. Essler, MD, J. Wantke, B. Mayer, K. Scheidhauer, R.A. Bundschuh, B. Haller, S.T. Astner, M. Molls, N. Andratschke

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the diagnostic value of positron-emission tomography/computed tomography (PET/CT) in stage I lung cancer patients treated with stereotactic body radiation therapy (SBRT), who have suspicious or unclear local recurrence findings in CT 1 year after treatment.

Patients and methods

A group of 29 patients with unclear or suspicious CT findings 1 year after SBRT were examined with PET/CT. The ability of standard uptake values (SUV_max, SUV_mean and posttherapeutic reduction in SUV) to detect local failure and identify patients at a high risk of disease-specific death was evaluated using logrank statistics. Histology and clinical follow-up were the gold standards for local recurrence.

Results

SUV_mean greater than 3.44 (p = 0.001); SUV_max greater than 5.48 (p = 0.009) or a relative reduction in SUV_mean or SUV_max of less than 43 (p = 0.030) or 52 % (p = 0.025), respectively, was indicative of local recurrence. These parameters also correlated with an increased risk of disease-specific death: SUV_mean greater than 2.81 (p = 0.023); SUV_max greater than 3.45 (p = 0.007) or a relative reduction in SUV_mean or SUV_max of less than 32 (p = 0.015) or 52 % (p = 0.013), respectively, was indicative of an increased risk of disease-specific death.

Conclusion

PET/CT performed 1 year after SBRT can reliably identify local recurrence and therefore help to clarify unclear CT findings. As posttherapeutic glucose metabolism also correlates with disease-specific survival, PET/CT may help to stratify lung cancer patients for additional treatment 1 year after SBRT.

Andratschke N, Zimmermann F, Boehm E et al (2011) Stereotactic radiotherapy of histologically proven inoperable stage I non-small cell lung cancer: patterns of failure. Radiother Oncol 101(2):245–249PubMedCrossRef

Nath SK, Sandhu AP, Kim D et al (2011) Locoregional and distant failure following image-guided stereotactic body radiation for early-stage primary lung cancer. Radiother Oncol 99(1):12–17PubMedCrossRef

Taremi M, Hope A, Dahele M et al (2011) Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients. Int J Radiat Oncol Biol Phys 82(2):967–973PubMedCrossRef

Baumann P, Nyman J, Hoyer M et al (2009) Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 27(20):3290–3296PubMedCrossRef

Bradley JD, El Naqa I, Drzymala RE et al (2010) Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant. Int J Radiat Oncol Biol Phys 77(4):1146–1150PubMedCrossRef

Fakiris AJ, McGarry RC, Yiannoutsos CT et al (o J) Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 75(3):677–882CrossRef

Oshiro Y, Aruga T, Tsuboi K et al (2010) Stereotactic body radiotherapy for lung tumors at the pulmonary hilum. Strahlenther Onkol 186:274–279PubMedCrossRef

Hof H, Hoess A, Oetzel D et al (2007) Stereotactic single-dose radiotherapy of lung metastases. Strahlenther Onkol 183(3):673–678PubMedCrossRef

Wulf J, Hädinger U, Oppitz U et al (2001) Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol 177(12):645–655PubMedCrossRef

10.

Bundschuh RA, Andratschke N, Dinges J et al (2012) Respiratory gated [18F]FDG PET/CT for target volume delineation in stereotactic radiation treatment of liver metastases. Strahlenther Onkol 188(7):592–598PubMedCrossRef

11.

Zamboglou C, Messmer MB, Becker Get al (2012) Stereotactic radiotherapy in the liver hilum. Basis for future studies. Strahlenther Onkol 188(1):35–41PubMedCrossRef

12.

Autorino R, Pompucci A, D’Agostino GR et al (2011) Whole-brain radiotherapy combined with surgery or stereotactic radiotherapy in patients with brain oligometastases: long-term analysis. Strahlenther Onkol 187(7):421–425PubMedCrossRef

13.

Scorsetti M, Mancosu P, Navarria P (2011) Stereotactic body radiation therapy (SBRT) for adrenal metastases: a feasibility study of advanced techniques with modulated photons and protons. Strahlenther Onkol 187(4):238–244PubMedCrossRef

14.

Graziano SL (1997) Non-small cell lung cancer: clinical value of new biological predictors. Lung Cancer Suppl 1:S37–S58CrossRef

15.

Kanters SD, Lammers JW, Voest EE (1995) Molecular and biological factors in the prognosis of non-small cell lung cancer. Eur Respir J 8(8):1389–1397PubMedCrossRef

16.

Liu L, Wu C, Wang Y et al (2011) Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival. J Thorac Oncol 6(11):1793–1800PubMedCrossRef

17.

Takahashi N, Suzuki K, Takamochi K, Oh S (2011) Prognosis of surgically resected lung cancer with extremely high preoperative serum carcinoembryonic antigen level. Gen Thorac Cardiovasc Surg 59(10):699–704PubMedCrossRef

18.

Eschmann SM, Friedel G, Paulsen F et al (2007) 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eur J Nucl Med Mol Imaging 34(1):463–471PubMedCrossRef

19.

Hicks RJ, Mac Manus MP, Matthews JP et al (2004) Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 60(2):412–418PubMedCrossRef

20.

Mac Manus MP, Hicks RJ, Matthews JP et al (2003) Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 21(7):1285–1292CrossRef

21.

Vahdat S, Oermann EK, Collins SP et al (2010) CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment. J Hematol Oncol 3:6PubMedCrossRef

22.

Henderson MA, Hoopes DJ, Fletcher JW et al (2010) A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 76(3):789–795PubMedCrossRef

23.

Wiegman EM, Pruim J, Ubbels JF et al (2011) 18F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study. Eur J Nucl Med Mol Imaging 38(6):1059–1063PubMedCrossRef

24.

Zimmermann FB, Geinitz H, Schill S et al (2006) Stereotactic hypofractionated radiotherapy in stage I (T1–2 N0 M0) non-small-cell lung cancer (NSCLC). Acta Oncol 45(7):796–801PubMedCrossRef

25.

Hothorn T, Zeileis A (2008) Generalized maximally selected statistics. Biometrics 64(4):1263–1269PubMedCrossRef

26.

Dignam JJ, Kocherginsky MN (2008) Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol 26(24):4027–4034PubMedCrossRef

27.

R Development Core Team (2011) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. http://www.R-project.org/

28.

Hothorn T, Hornik K, Weil MA van de et al (2006) A lego system for conditional inference. Am Stat 60(10):257–263CrossRef

29.

Mac Manus MP, Hicks RJ, Matthews JP et al (2005) Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer 49(1):95–108CrossRef

30.

Zhang X, Liu H, Balter P et al (2012) Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 83(5):1558–1565PubMedCrossRef

31.

Bollineni VR, Widder J, Pruim J et al (2012) Residual 18F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control. Int J Radiat Oncol Biol Phys 83(4):e551–e555PubMedCrossRef

32.

Andratschke N (2012) Stereotactic ablative radiotherapy for inoperable stage I NSCLC. Lancet Oncol 13(8):746–748PubMedCrossRef

33.

Dunlap NE, Yang W, McIntosh A et al (2012) Computed tomography-based anatomic assessment overestimates local tumor recurrence in patients with mass-like consolidation after stereotactic body radiotherapy for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 84(5):1071–1077PubMedCrossRef

Titel: Positron-emission tomography CT to identify local recurrence in stage I lung cancer patients 1 year after stereotactic body radiation therapy
verfasst von: Prof. Dr. M. Essler, MD
J. Wantke
B. Mayer
K. Scheidhauer
R.A. Bundschuh
B. Haller
S.T. Astner
M. Molls
N. Andratschke
Publikationsdatum: 01.06.2013
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 6/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-013-0310-9

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Positron-emission tomography CT to identify local recurrence in stage I lung cancer patients 1 year after stereotactic body radiation therapy